We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
The Michigan researchers conducted two trials with escitalopram, both lasting eight weeks.
2
Method: Thirty-one adults with NES participated in a 12-week open-label trial of escitalopram.
3
Discussion: This open-label trial of escitalopram showed significant reductions in symptoms associated with NES.
4
These results suggest that escitalopram may be an effective and safe treatment for pediatric SAD.
5
Lamotrigine combined with escitalopram presented with a better antidepressant effect and safety, with higher patient tolerance.
6
Increased 5-HT transporter function under conditions of dietary restriction might contribute to the decreased effect of escitalopram.
7
Twenty outpatients with a primary diagnosis of SAD were treated in a 12-week open trial with escitalopram.
8
The sessions began approximately three hours after ingestion of 20 mg escitalopram or placebo presented in pseudorandom order.
9
Neither amitriptyline nor escitalopram appeared to affect GE or meal-induced satiety after the 10-week period in any group.
10
The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate.
11
Conclusions: Responses to escitalopram and predictors of PSD 3 months following stroke differed based on the presence of baseline depression.
12
Part of them were additionally treated with escitalopram, whereas the other group only consulted to a dermatological and psychiatric follow-up.
13
Specifically, it validated the dominant and invariable expression of cerebral pattern I after application of a single dose of escitalopram.
14
Objective: The aim of our study was to compare the efficacy and safety of escitalopram vs citalopram in Chinese MDD patients.
15
According to the new findings, Forest Laboratories' Lexapro, also called escitalopram, reduces neither the severity nor frequency of hot flashes associated with menopause.
16
Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression.